Integrated BioPharma amends credit agreement to replace LIBOR with Term SOFR plus 0.10%

INTEGRATED BIOPHARMA INC

Fourth Amendment to Revolving Credit, Term Loan and Security Agreement dated March 16, 2023.
Interest rate benchmark changed from LIBOR to Term SOFR Rate plus a 10 basis point SOFR Adjustment.
Outstanding LIBOR-based loans may remain until their term; new requests use Term SOFR.
As of March 16, 2023, no outstanding borrowings or pending requests under the agreement.
Amendment involves Integrated BioPharma and its subsidiaries with PNC Bank as agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.